93 related articles for article (PubMed ID: 20506203)
1. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis?
Lehman TJ
Arthritis Rheum; 2010 Aug; 62(8):2183-4. PubMed ID: 20506203
[No Abstract] [Full Text] [Related]
2. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.
Diak P; Siegel J; La Grenade L; Choi L; Lemery S; McMahon A
Arthritis Rheum; 2010 Aug; 62(8):2517-24. PubMed ID: 20506368
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
Yildirim-Toruner C; Kimura Y; Rabinovich E
J Rheumatol; 2008 Aug; 35(8):1680-1. PubMed ID: 18671328
[No Abstract] [Full Text] [Related]
4. Adalimumab in juvenile rheumatoid arthritis.
Taddio A; Marchetti F
N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
[No Abstract] [Full Text] [Related]
5. [Tolerance of biological agents in children].
Bader-Meunier B
Arch Pediatr; 2010 Jun; 17(6):962-3. PubMed ID: 20654981
[No Abstract] [Full Text] [Related]
6. Tumor necrosis factor blockers in rheumatoid arthritis.
Pisetsky DS
N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
[No Abstract] [Full Text] [Related]
7. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
8. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
[No Abstract] [Full Text] [Related]
9. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
10. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
Passo M
Curr Probl Pediatr Adolesc Health Care; 2006 Mar; 36(3):97-103. PubMed ID: 16473286
[No Abstract] [Full Text] [Related]
12. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
[TBL] [Abstract][Full Text] [Related]
13. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis and treatment with infliximab.
Myers A; Clark J; Foster H
N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859881
[No Abstract] [Full Text] [Related]
15. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
[TBL] [Abstract][Full Text] [Related]
16. New treatments for juvenile idiopathic arthritis.
Hashkes PJ; Friedland O; Uziel Y
Isr Med Assoc J; 2002 Jan; 4(1):39-43. PubMed ID: 11802310
[No Abstract] [Full Text] [Related]
17. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
18. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.
Peek R; Scott-Jupp R; Strike H; Clinch J; Ramanan AV
Ann Rheum Dis; 2006 Sep; 65(9):1259. PubMed ID: 16905590
[No Abstract] [Full Text] [Related]
20. Adalimumab in juvenile rheumatoid arthritis.
Sfriso P; Ravaioli F
N Engl J Med; 2008 Dec; 359(23):2495; author reply 2496-7. PubMed ID: 19052133
[No Abstract] [Full Text] [Related]
[Next] [New Search]
